New York, June 4, 2026, 11:03 EDT
Progyny Inc. shares rose Thursday morning, stretching a rebound as investors responded to analyst backing and steady member demand at the fertility-benefits provider.
The stock gained 84 cents, or roughly 3.4%, to $25.83 as of 10:45 a.m. EDT. Shares changed hands between $25.01 and $25.87 earlier. The company had a market cap of about $2.19 billion.
The move stands out as the stock was already up about 35% over the past month and around 41% over three months, a quick jump for a name still compared to slower headline growth and a previous big-client shift. Simply Wall St said Wednesday the surge pushed investors to revisit a basic question: is the market still undervaluing the company’s growth, or has it already priced it in?
Broker calls gave Progyny a lift. Bank of America bumped its target up to $31 from $29 on June 2, sticking with its buy rating. MarketBeat reported the stock shows an average “Moderate Buy” and a $29.67 target. A price target is where brokers think the stock could trade, but it’s not guaranteed. MarketBeat
Small-cap investor Voya MI Dynamic Small Cap Fund flagged another reason for the market to watch the stock. The fund said Progyny shares slipped after results, hit by cautious 2026 guidance and “administrative reductions in reported covered lives,” but said “underlying demand and execution” held up. Covered lives refers to the employees and dependents on client plans. Insider Monkey
Progyny (PGNY) reported record revenue for the first quarter on May 7, coming in at $328.5 million. Net income hit $24.2 million and gross margin landed at 25.3%. Revenue rose 12.2% if you back out $31.3 million from a big client that didn’t renew last year. CEO Pete Anevski said member engagement “trended to the higher end.” CFO Mark Livingston pointed to “topline growth, increased gross margin.” Adjusted EBITDA slipped 2.1% to $56.6 million, with Progyny investing into its platform. GlobeNewswire
Progyny put out guidance for 2026 revenue at $1.365 billion to $1.405 billion, saying it expects more than 600 clients with 7.2 million covered lives when 2026 launches are up and running. For Q2, Progyny is looking for revenue between $342 million and $355 million.
Capital returns are in focus, with Progyny announcing on May 26 that the board has cleared a share buyback of up to $200 million. The move will use cash the company already has. Share buybacks shrink the outstanding share count, but Progyny said this program could pause or end at any time.
Progyny is up against a close field. It offers fertility and women’s health benefits to employers and health plans, but faces competition from traditional insurers with fertility options, Carrot Fertility, and Maven Clinic, according to StockStory. Rivalry for employer benefit spending is in focus now, with Progyny’s renewal cycle and sales pitch under scrutiny after the shares moved.
The trade still carries a clear downside. Tighter employer benefit budgets or more competition in fertility benefits could hit growth and margins. The company has already shown one large-client transition can muddy the numbers; utilization, or how often eligible members actually use the benefit, can swing results, too. If investors have already priced in too much second-half improvement, a soft Q2 could mean less room to miss.
Progyny is trading like a name with something to prove, not just another small-cap healthcare stock with problems. The company has to deliver on member growth, show a solid selling season and turn promised cash returns into real per-share gains, rather than just putting them in guidance.
